Current advances and challenges in HIV-1 vaccines.
Curr HIV/AIDS Rep
; 3(1): 39-47, 2006 Feb.
Article
en En
| MEDLINE
| ID: mdl-16522258
ABSTRACT
Recent advances in science, which have aided HIV-1 vaccine development, include an improved understanding of HIV-1 envelope structure and function, expansion of the pipeline with innovative vaccine strategies, promising multi-gene and multi-clade vaccines that elicit cellular immunity, conduct of clinical trials in a global network, and development of validated techniques that enable simultaneous measurement of multiple T cell vaccine-induced immune responses in humans. A common feature of several preventive vaccine strategies now in early clinical trials is their ability in nonhuman primates to attenuate clinical disease rather than completely prevent HIV-1 infection. One vaccine concept has been tested in large-scale clinical trials, two are currently in efficacy trials, and one more is poised to enter efficacy trial in the next few years. Simultaneously, expanded efforts continue to identify new designs that induce mucosal immunity as well as broadly neutralizing antibodies.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
VIH-1
/
Vacunas contra el SIDA
/
Alergia e Inmunología
Límite:
Humans
Idioma:
En
Revista:
AIDS Rep
Asunto de la revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Año:
2006
Tipo del documento:
Article
País de afiliación:
Estados Unidos